TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02358889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hI-con1
Description: Intravitreal injection of hI-con1 0.3 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hI-con1
Description: Intravitreal injection of hI-con1 0.3 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Intravitreal injection of ranibizumab 0.5 mg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Intravitreal injection of ranibizumab 0.5 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: No injection is given, a needleless syringe is used to mimic an injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: No injection is given, a needleless syringe is used to mimic an injection.
Study: NCT03049163

Intervention type: DRUG
Group type: OTHER
Intervention: vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]
Description: to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]
Description: to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
Study: NCT04046471

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: enhanced Stop Light Diet
Description: Stop light diet enhanced with portion-controlled meals

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: enhanced Stop Light Diet
Description: Stop light diet enhanced with portion-controlled meals

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Remote
Description: Participants will receive remotely delivered weight loss in a group setting.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individual In-Person
Description: Participants will receive a weight loss intervention during individual, at-home visits.
Study: NCT01850004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study: NCT02816216

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CampAir
Description: An empirically-based dynamic e-health intervention (based on the evidence-based ASMA) to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control.
Study: NCT04160299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance-based exergaming
Description: Dance sessions
Study: NCT00999349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin (LEGALON)
Description: Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
Study: NCT03725436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDM2/MDMX Inhibitor ALRN-6924
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT01262391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension 2.5 mg
Description: Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 2.5 mg of solifenacin once daily in adults.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension 2.5 mg
Description: Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 2.5 mg of solifenacin once daily in adults.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension 5 mg
Description: Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 5 mg dose of solifenacin once daily in adults.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension 5 mg
Description: Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 5 mg dose of solifenacin once daily in adults.
Study: NCT00999349

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01245179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~1. 15 mg MWF 3 weeks on, 1 week off (if needed)~2. 15 mg MWF every week (starting dose)~3. 20 mg MWF 3 weeks on, 1 week off~4. 20 mg MWF every week
Study: NCT00428610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636-sodium
Description: LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
Study: NCT00906646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metabolic therapy
Description: Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT01262391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension 10 mg
Description: Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses 10 mg dose of solifenacin once daily in adults.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension 10 mg
Description: Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses 10 mg dose of solifenacin once daily in adults.
Study: NCT02851238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving Pressure Limited Ventilation
Description: Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 2 to 10 cmH2O during one-lung ventilation
Study: NCT02386202

Intervention type: OTHER
Intervention: No intervention
Description: No interventions
Study: NCT01831375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speak Up
Description: Intervention group_treatment group

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Get connected
Description: Participants will learn to be connected with social resources in the community.
Study: NCT01970202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40mg Enoxaparin
Description: Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60mg Enoxaparin
Description: Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: no treatment
Study: NCT05451576

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zelnite®
Description: 2pc intravenous Zelnite® will be given for 7 weeks (5 days/week).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given for 7 weeks (5 days/week).
Study: NCT00466960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies
Study: NCT04114058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal bupivicaine
Description: local field infiltration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca blockade
Description: fascia iliaca compartment blockade
Study: NCT02995395

Intervention type: DEVICE
Intervention: Mucosal Impedance Balloon catheter
Description: During the clinical endoscopy (a standard procedure that allows your doctor to look at the inside of your swallowing tube), the 2 mm catheter (tiny tube), called an Intraluminal Impedance Balloon, will be passed through the channel of the standard endoscope.~o The catheter (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) for two minutes, readings from the catheter will be recorded.
Study: NCT01947803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.
Study: NCT04613297

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline and during hospitalization blood samples
Description: Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :~* at day 3~* day 5 and~* In case of aggravation~* At the discharge from hospital

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline blood sample
Description: Blood sample will be performed at the inclusion visit only

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline blood sample
Description: Blood sample will be performed at the inclusion visit only
Study: NCT01978405

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpha lipoic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid
Study: NCT03436472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: low-dose dexmedetomidine infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline infusion
Study: NCT02799745

Intervention type: OTHER
Group type: OTHER
Intervention: Active Surveillance
Study: NCT03094143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic valve intervention
Description: The choice of either surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) will be made by the local clinical team according to local policies. In patients undergoing surgical replacement the choice of surgical technique and type of valve replacement used will be at the discretion of the operating surgeon. Patients found to have significant coronary artery disease requiring concomitant coronary artery bypass surgery will not be excluded. Similarly the choice of TAVI valve and need for percutaneous coronary intervention will be made by the TAVI heart team. The procedure should be performed as soon as possible and ideally within four months of randomisation and allocation to group A.
Study: NCT04688554

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI and DTI
Description: Neurologic imaging correlates

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI and DTI
Description: Neurologic imaging correlates

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI and DTI
Description: Neurologic imaging correlates
Study: NCT03989102

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sterile isotonic (0.9%) normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe; and will be used as a placebo, rather than a comparator vaccine
Study: NCT01741038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim®
Description: AlloStim® is derived from the blood of normal blood donors and is intentionally mismatched to the recipient. CD4+ T-cells are separated from the blood and differentiated and expanded for 9-days in culture to make an intermediary called T-Stim. AlloStim is made by incubating T-Stim cells for 4h with antibody coated microbeads. The cells with the beads still attached are suspended in infusion media and loaded into syringes. The syringes are shipped refrigerated to the point-of-care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cryoablation
Description: percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.

Intervention type: OTHER
Group type: OTHER
Intervention: Physician's Choice (PC)
Description: Physician's Choice therapy can consist of best supportive care (BSC) or any US-FDA approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated
Study: NCT02339168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO
Study: NCT04973488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange
Description: The intervention is a combination between the procedure of Therapeutic plasma exchange and biological transfusion of convalescent plasma from donors that have have COVID-19
Study: NCT01103531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Exercise
Description: Aerobic and resistance exercise for 24 exercise training sessions over an 8-week period (three times weekly).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational information about health topics
Description: A counselor will meet with participants for 24 sessions (3 times/week) over an 8-week period to present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
Study: NCT00265811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfox

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT00827892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
Study: NCT02186964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tension free primary closure
Description: tension free primary closure of the defects created by excision of the pilonidal sinus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: karydakis
Description: the defect after excision of the pilonidal sinus is closed by Karydakis procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limberg flap
Description: defect after excision of the pilonidal sinus is closed by Limberg flap procedure
Study: NCT01243385

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
Study: NCT02447991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Description: During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
Study: NCT04108039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRh antagonist
Description: In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles \>14mm or E2 levels \>400 pg/ml and continuing until ovulation triggering to avoid LH surge in COS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: Micronized progesterone protocol to avoid LH surge in COS, from stimulation day 1 and continuing until ovulation triggering.
Study: NCT01187589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsehaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulizer & Albuterol 0.5ml
Description: Albuterol aerosolized by a nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulizer & Albuterol 0.5ml
Description: Albuterol aerosolized by a nebulizer
Study: NCT00079352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study: NCT02766491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening and stretching
Description: Strengthening exercises will be performed 4 times a week for 10 weeks. Single leg heel raises will be the preferred exercise performed. The group of participants will have a wide range of strength and functional abilities, this will be accounted for with individualised programmes. The exercise load can be reduced by switching to bilateral heel raises, giving external support, reducing the range of motion or performing the heel raises while seated. Exercise load will be progressively increased by adding weight in the form of water bottles to a rucksack worn on the participant's back.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional stretching
Description: This group will perform seated biceps curls 4 times a week for 10 weeks, where extra load can be added progressively by holding water bottles in the hand.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed.
Study: NCT04442516

Intervention type: OTHER
Intervention: Questionnaire, sampling of blood, urine and saliva
Description: We are following patients who are receiving Cisplatin as part of their cancer therapy.

Intervention type: OTHER
Intervention: Questionnaire, sampling of blood, urine and saliva
Description: We are following patients who are receiving Cisplatin as part of their cancer therapy.
Study: NCT02256046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscope
Description: Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
Study: NCT03545126

Intervention type: OTHER
Intervention: 13C6 Leucine
Description: Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)

Intervention type: OTHER
Intervention: 13C6 Leucine
Description: Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)

Intervention type: OTHER
Intervention: 13C6 Leucine
Description: Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)
Study: NCT04455386

Intervention type: DIAGNOSTIC_TEST
Intervention: Stress radiography,Anterior drawer test,Stress ultrasound,Computed tomography, Magnetic resonance imaging,Arthroscopy
Description: All patients suspected chronic ankle instability, will perform an anterior drawer test, stress ultrasound, computed tomography, magnetic resonance imaging of ankle. Patients with chronic ankle instability will be recommended to perform an arthroscopic repair if non-operative treatment failed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stress radiography,Anterior drawer test,Stress ultrasound,Computed tomography, Magnetic resonance imaging,Arthroscopy
Description: All patients suspected chronic ankle instability, will perform an anterior drawer test, stress ultrasound, computed tomography, magnetic resonance imaging of ankle. Patients with chronic ankle instability will be recommended to perform an arthroscopic repair if non-operative treatment failed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stress radiography,Anterior drawer test,Stress ultrasound,Computed tomography, Magnetic resonance imaging,Arthroscopy
Description: All patients suspected chronic ankle instability, will perform an anterior drawer test, stress ultrasound, computed tomography, magnetic resonance imaging of ankle. Patients with chronic ankle instability will be recommended to perform an arthroscopic repair if non-operative treatment failed.
Study: NCT01295606

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Cefazolin
Description: iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
Study: NCT03541746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: After hysteroscopic adhesiolysis, 30 patients will undergo once injection of 5ml PRP into the wall then lining the uterine cavity by 5ml platelet rich plasma gel. Finally, Foley balloon catheter will be inserted intrauterine then inflated and cutting its stem and to be left for two weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Foley's Catheter
Description: After hysteroscopic adhesiolysis, 30 patients will undergo intrauterine insertion of one inflated Foley balloon catheter with cutting its stem only to be left for two weeks.
Study: NCT03154710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOOVCARE
Description: web-mediated follow up